Robert S. Janssen

Neurology

2929 7th St Ste 100
Berkeley, CA 94710

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

A narrative review of immune-mediated adverse events in clinical trials of CpG oligonucleotide toll-like receptor 9 agonists.

A narrative review of immune-mediated adverse events in clinical trials of CpG oligonucleotide toll-like receptor 9 agonists.

Journal: Vaccine

Published: December 23, 2025

Hepatitis B vaccination with HepB-CpG in people living with HIV: a narrative review.

Hepatitis B vaccination with HepB-CpG in people living with HIV: a narrative review.

Journal: Expert review of vaccines

Published: May 08, 2025

Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.

Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 03, 2025

Phase 1 trial of an investigational Tdap booster vaccine with CpG 1018 adjuvant compared with Boostrix in healthy adults and adolescents.

Phase 1 trial of an investigational Tdap booster vaccine with CpG 1018 adjuvant compared with Boostrix in healthy adults and adolescents.

Journal: Vaccine

Published: March 18, 2024

Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease.

Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease.

Journal: Vaccine

Published: December 22, 2022

Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study.

Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study.

Journal: Human vaccines & immunotherapeutics

Published: October 21, 2022

Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial.

Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: August 05, 2022

An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay.

An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay.

Journal: Vaccine

Published: July 19, 2022

An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901.

An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901.

Journal: Vaccines

Published: March 03, 2022

Safety and immunogenicity of HepB-CpG in women with documented pregnancies post-vaccination: A retrospective chart review.

Safety and immunogenicity of HepB-CpG in women with documented pregnancies post-vaccination: A retrospective chart review.

Journal: Vaccine

Published: November 27, 2021

Adult immunization against hepatitis B: Does the number of jabs matter?

Adult immunization against hepatitis B: Does the number of jabs matter?

Journal: Vaccine

Published: November 05, 2021

Considerations for estimating real-world outcomes and value in vaccination: A case study with adult hepatitis B virus vaccination.

Considerations for estimating real-world outcomes and value in vaccination: A case study with adult hepatitis B virus vaccination.

Journal: Vaccine

Published: April 23, 2021

Showing 1-12 of 28

Last Updated: 09/26/2026